JP2021536494A5 - - Google Patents

Info

Publication number
JP2021536494A5
JP2021536494A5 JP2021513276A JP2021513276A JP2021536494A5 JP 2021536494 A5 JP2021536494 A5 JP 2021536494A5 JP 2021513276 A JP2021513276 A JP 2021513276A JP 2021513276 A JP2021513276 A JP 2021513276A JP 2021536494 A5 JP2021536494 A5 JP 2021536494A5
Authority
JP
Japan
Prior art keywords
formulation
use according
liver disease
per dose
carnitine
Prior art date
Application number
JP2021513276A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020049549A5 (https=
JP2021536494A (ja
Filing date
Publication date
Priority claimed from IL261670A external-priority patent/IL261670B/en
Application filed filed Critical
Publication of JP2021536494A publication Critical patent/JP2021536494A/ja
Publication of JPWO2020049549A5 publication Critical patent/JPWO2020049549A5/ja
Publication of JP2021536494A5 publication Critical patent/JP2021536494A5/ja
Pending legal-status Critical Current

Links

JP2021513276A 2018-09-06 2019-06-27 マグネシウム含有製剤及びその使用 Pending JP2021536494A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL261670A IL261670B (en) 2018-09-06 2018-09-06 Magnesium-containing formulation and uses thereof
IL261670 2018-09-06
PCT/IL2019/050717 WO2020049549A1 (en) 2018-09-06 2019-06-27 Magnesium-containing formulation and uses thereof

Publications (3)

Publication Number Publication Date
JP2021536494A JP2021536494A (ja) 2021-12-27
JPWO2020049549A5 JPWO2020049549A5 (https=) 2022-06-30
JP2021536494A5 true JP2021536494A5 (https=) 2022-06-30

Family

ID=63998430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513276A Pending JP2021536494A (ja) 2018-09-06 2019-06-27 マグネシウム含有製剤及びその使用

Country Status (6)

Country Link
US (1) US20210322465A1 (https=)
EP (1) EP3846779A4 (https=)
JP (1) JP2021536494A (https=)
CA (1) CA3111618A1 (https=)
IL (1) IL261670B (https=)
WO (1) WO2020049549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265603A1 (en) * 2019-06-25 2022-08-25 National Hospital Organization Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018137C (en) * 1989-06-14 2000-01-11 Thomas Scholl L-carnitine magnesium citrate
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
US6608222B2 (en) * 2000-11-21 2003-08-19 Alpha Food Ingredients, Inc. Bioactive conjugated linoleic acid glycerides and method of use
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20130236529A1 (en) * 2012-03-09 2013-09-12 Flavitpure, Inc. Composition and methods to enhance anti-oxidation, gut flora and immunity in pets
EA201890618A1 (ru) * 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
MX2018003926A (es) * 2015-10-02 2018-09-06 Balchem Corp Composicion para mejorar el rendimiento.
KR101782134B1 (ko) * 2015-12-11 2017-09-26 (주) 머니키 카르시니아캄보지아 추출물을 함유한 건강보조식품
RU2629606C1 (ru) * 2016-08-01 2017-08-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Применение соединения магния, обладающего гепатопротекторной активностью, для лечения алкогольного и лекарственного гепатита

Similar Documents

Publication Publication Date Title
JP5085541B2 (ja) 疲労軽減剤
JP2015500285A5 (https=)
CN104248632A (zh) 瓜氨酸或其盐和精氨酸或其盐提高血液精氨酸水平的用途
JP2008529979A (ja) クレアチンヒドロキシクエン酸塩およびその製造法および個体における使用
EP2907517A1 (en) Composition comprising myricetin as active ingredient for enhancing exercise performance or fatigue recovery
EP3115047B1 (en) Debility preventative
US11896598B2 (en) Appetite suppressant compositions and methods thereof
JP2024101004A (ja) 暑熱ストレス緩和剤
JP6218870B2 (ja) ジンセノサイドｆ２を含む非アルコール性肝疾患又はインスリン抵抗性の予防若しくは治療用組成物
CN101296693B (zh) 持久力提高剂
JP2021536494A5 (https=)
JP2025535179A (ja) カンナビジオール及びタウリンを含む歯周炎の予防又は治療用組成物
RU2016137926A (ru) Композиции грапипранта и способы их применения
JP5281268B2 (ja) 筋力向上剤
JP2021525775A (ja) がん悪液質において用いる化合物
JP5066448B2 (ja) 口内炎の予防または治療のための組成物および方法
JPWO2019232130A5 (https=)
JPWO2020049549A5 (https=)
RU2670612C2 (ru) Композиция для предупреждения или лечения ожирения, содержащая α-липоевую кислоту и N-ацетилцистеин в качестве активных ингредиентов
JPWO2007077995A1 (ja) 筋肉増量剤
JP6554292B2 (ja) 持久力向上作用又は抗疲労作用を発揮させる方法
US20050043287A1 (en) Composition comprising L-arginine as a muscle growth stimulant and use thereof
ES2211334B1 (es) Suplemento nutricional para el tratamiento de sindromes relacionados con la fatiga.
JP6594858B2 (ja) メラトニン分泌調整剤、メラトニン分泌調整方法
JP2021536494A (ja) マグネシウム含有製剤及びその使用